Minute Insight: Acutus Adds Another Device To The Left-Heart Business It Sold To Medtronic
Executive Summary
The company announced the US launch of the AcQCross Qx transseptal dilator/needle. It is specifically designed to help deploy Boston Scientific’s Watchman left-atrial appendage closure device, but it is part of the left-heart access device portfolio that Acutus recently sold to Medtronic.
You may also be interested in...
Exec Chat: PFA, Patient Monitoring, Modular CRM Open Opportunities For Boston Scientific
In an interview with Medtech Insight, Angelo De Rosa, the general manager of Boston Scientific’s cardiac rhythm management and electrophysiology businesses in Europe, Middle East and Africa (EMEA), discussed some of his company’s recent achievements and the opportunities it is addressing in 2022.
Inflation, Supply Chain Headaches And Staffing Shortages: CEOs Talk About 'Big Picture' Challenges
Although procedure volumes have mostly recovered from the shock of COVID-19 two years ago, the effects of the pandemic on the medtech sector and the economy overall will be felt for years to come. In recent analyst and sales and earnings presentations, CEOs of major medtech companies faced questions about how their company is handling these major "macro" issues.
Minute Insight: NeuroOne Amends Deal With Zimmer Biomet To Shore Up Balance Sheet
Zimmer Biomet agreed to amend its exclusive development and distribution agreement with NeuroOne to pay $3.5m for 350,000 of stock. The deal will help NeuroOne continue to develop its Evo stereoelectroencephalography brain-mapping electrodes without further diluting the company’s stock.